FATE Q1 2023 Earnings — Fate Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FATEFate Therapeutics, Inc.

$158M

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$59M+220.3% YoY

Gross Profit

-$7M-11.3% margin

Operating Income

-$29M-48.5% margin

Net Income

-$19M-32.0% margin

EPS (Diluted)

$-0.09

QoQ Revenue Growth

+33.0%

Cash Flow

Operating Cash Flow

-$29M

Free Cash Flow

-$32M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$630M

Total Liabilities

$153M

Stockholders' Equity

$477M

Cash & Equivalents

$42M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$59M	$18M	+220.3%
Gross Profit	-$7M	-$54M	+87.6%
Operating Income	-$29M	-$74M	+61.6%
Net Income	-$19M	-$66M	+71.3%

Revenue Segments

Upfront Fee And Equity Premium

$31M100%